May 19 2012 Prednisone, Azathioprine, and N-Acetylcysteine for Pulmonary Fibrosis

The Idiopathic Pulmonary Fibrosis Clinical Research Network

N Engl J Med 2012;  366:1968-1977May 24, 2012DOI:  10.1056/NEJMoa1113354

Idiopathic pulmonary fibrosis is a chronic, progressive lung disease of unknown cause characterized by the histopathological pattern of usual interstitial pneumonia.1 The median survival of patients with idiopathic pulmonary fibrosis after diagnosis is 2 to 5 years.1

The use of glucocorticoids or immunosuppressive agents has been the conventional approach to the treatment of patients with this disease. A consensus-based guideline suggested that a two-drug regimen (a combination of prednisone and either azathioprine or cyclophosphamide) be used in a subgroup of patients with idiopathic pulmonary fibrosis.2 A survey of pulmonologists showed that almost 50% used a regimen of either two drugs (azathioprine plus prednisone) or three drugs (azathioprine, prednisone, and N-acetylcysteine [NAC]) when therapy was offered to their patients with mild idiopathic pulmonary fibrosis.3

 

Read the entire article at:

http://www.nejm.org/doi/full/10.1056/NEJMoa1113354?query=featured_home

For more information about Idiopathic Pulmonary Fibrosis please visit: www.ipftoday.com

 

This entry was posted in Interstitial Lung Disease, IPF, Medical, Pulmonary Fibrosis, Uncategorized and tagged , , , , , . Bookmark the permalink.

Leave a Reply

Your email address will not be published. Required fields are marked *

You may use these HTML tags and attributes: <a href="" title=""> <abbr title=""> <acronym title=""> <b> <blockquote cite=""> <cite> <code> <del datetime=""> <em> <i> <q cite=""> <s> <strike> <strong>